Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP1027 | DOI: 10.1530/endoabs.81.EP1027

ECE2022 Eposter Presentations Thyroid (219 abstracts)

Is obesity linked to thyroid cancer?

Iustin-Daniel Toma1, Raluca-Alexandra Trifănescu1,2, Maria-Alexandra Mohora1, Ionela Florina Baciu1, 2, Nicoleta Baculescu1, 2, Cristina Ana-Maria Căpăţînă1,2, Roxana Duşceac1,2, Simona Andreea Găloiu1,2, Dan Alexandru Niculescu1, 2, Marian Romeo Smărăndache3, Dumitru Lucian Ioachim4 & Cătălina Poiană1,2


1National Institute of Endocrinology ‘C.I. Parhon‘, Pituitary and Neuroendocrine Disorders, Bucharest, Romania; 2University of Medicine and Pharmacy ‘Carol Davila‘, Endocrinology, Bucharest, Romania; 3National Institute of Endocrinology ‘C.I. Parhon‘, Endocrine Surgery, Bucharest, Romania; 4National Institute of Endocrinology ‘C.I. Parhon‘, Pathology, Bucharest, Romania


Background: During the past decades, the prevalence of both obesity and differentiated thyroid carcinoma increased worldwide. The link between obesity and thyroid cancer is controversial. Some studies found a relationship between obesity and thyroid carcinoma (especially BRAFV600E mutated) and between type 2 diabetes mellitus and thyroid cancer, while other did not.

Aim: To assess the relationship between papillary thyroid carcinoma and increased body mass index (BMI).

Methods: Retrospective study by analyzing the files of patients with thyroid nodules who underwent thyroid surgery within a tertiary endocrine center. 101 patients (aged 54.5±14 years) with thyroid nodules were included. TSH, FT4 were measured by chemiluminescence. Preoperatively, fine needle aspiration and cytology exam were performed in suspicious nodules, according to current guidelines. Bethesda classification was used for reporting the results. After thyroidectomy, according to histology exam, 51 patients had multinodular nontoxic (MNG) and 50 had papillary thyroid carcinoma (PTC).

Results: Globally, normal BMI (18.5-24.99 kg/m2) was found in 27% of patients, while 47%were overweight and 26% were obese. 43% of patients were residents in iodine-deficient regions without significant differences between patients with MNG and PTC. Cytology exam was performed in 57 patients: Bethesda II was described in 11 patients (19,3%), Bethesda IV in 23 (40,35%), Bethesda V in 13 (22,8%), Bethesda VI in 7(12,28%) and for two patients our results came back inconclusive (Bethesda I – 3,5%) and 1 more patient (1,75%) had cytology exam performed from ganglia which came back positive for malignancy. Age was similar in patients with MNG (55.6±12.3 years) and in patients with PTC (55±15.6 years, P= ns). Mean TSH levels were similar in patients with MNG (1.2±0,81 mIU/l) and in patients with PTC (1.4±0,78 mIU/l, P= ns). Mean diameter of the largest nodule was significantly higher in patients with multinodular goiter (31.3±12.6 mm) than in patients with PTC (26.3±12 mm, P=0.02). Patients with normal BMI had similar mean diameter of the largest nodule (29.9±15 mm) with overweight and obese patients (31.63±11.2 mm, P= ns, t-test) and also showed a similar prevalence of PTC- 48.2% as compared with 48.6% in overweight and obese patients (P= ns, chi square). Mean TSH levels was slightly higher (1.49±0,80 mIU/l) in overweight and obese patients with PTC, than in patients with normal BMI (TSH= 1.26±0,75 mIU/l, P=ns).

Conclusion: In our retrospective series, there was no link between BMI and papillary thyroid cancer. Larger prospective studies are needed in order to clarify this relationship.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts